文献速递妇科

纳入2018 FIGO分期的早期宫颈癌微创与开腹根治性子宫切除术结局比较

Outcomes of Minimally Invasive versus Open Radical Hysterectomy for Early Stage Cervical Cancer Incorporating 2018 FIGO Staging.
PubMed 文献 · J Minim Invasive Gynecol · 2020-07-28

单中心回顾性分析2007至2018年126例早期宫颈癌根治性子宫切除术患者,开腹44例(35%)、微创82例(65%),微创中腹腔镜49%、机器人51%。开腹组3年无病生存率95% vs 微创组87%(P=0.17),总生存率97% vs 92%(P=0.25),均未达统计学显著。14例复发患者中11例经2018 FIGO分期重新分为更高期别;微创复发患者接受辅助治疗1/9 vs 开腹3/5(P=0.05)。

要点

  • 开腹组3年无病生存率95% vs 微创组87%(P=0.17),总生存率97% vs 92%(P=0.25),均未达统计学显著。
  • 14例复发患者中11例经2018 FIGO分期重新分为更高期别(开腹5/5,微创6/9)。
  • 微创复发患者接受辅助治疗1/9 vs 开腹3/5(P=0.05)。

核心结论

  • 在类似Laparoscopic Approach to Cervical Cancer试验人群的队列中,2018 FIGO分期可能有助于细化早期宫颈癌微创根治性子宫切除术的适应证。
  • 微创与开腹途径结局差异可能由对National Comprehensive Cancer Network辅助治疗指南的依从性差异解释。

研究设计与样本

  • 回顾性分析,单中心教学医院,2007至2018年因IA1期伴淋巴血管浸润、IA2期或IB1期宫颈鳞癌、腺鳞癌或腺癌行根治性子宫切除术的患者,共126例符合纳入标准。
  • 开腹44例(35%),微创82例(65%);微创中腹腔镜49%、机器人51%。
  • 按2009 FIGO分期:IA1期伴淋巴血管浸润1例、IA2期15例、IB1期110例。

主要发现

  • 3年无病生存率开腹组95% vs 微创组87%(P=0.17),未达统计学显著。
  • 总生存率开腹组97% vs 微创组92%(P=0.25),未达统计学显著。
  • 14例复发患者按2009 FIGO分期均为IB1期;其中11/14经2018 FIGO分期重新分为更高期别(开腹5/5,微创6/9)。
  • 所有复发患者均基于Sedlis标准(10/14)或其他危险因素(4/14)推荐辅助治疗。
  • 复发患者中接受辅助治疗:微创组1/9 vs 开腹组3/5(P=0.05)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY OBJECTIVE: To compare outcomes after minimally invasive surgery (MIS) vs open radical hysterectomy for early stage cervical cancer incorporating 2018 Federation of Gynecology and Obstetrics (FIGO) staging. DESIGN: A retrospective analysis. SETTING: A single teaching hospital. PATIENTS: Patients after radical hysterectomy for stage IA1 with lymphovascular invasion, IA2, or IB1 squamous, adenosquamous, or adenocarcinoma of the cervix between 2007 and 2018, mirroring the Laparoscopic Approach to Cervical Cancer trial criteria. INTERVENTIONS: The use of MIS surgery for performing radical hysterectomy. MEASUREMENTS AND MAIN RESULTS: The outcomes were compared between patients undergoing MIS vs open approaches. A total of 126 patients met the inclusion criteria. The approach was open in 44 patients (35%) and MIS in 82 patients (65%); 49% were laparoscopic and 51% were robotic. Distribution based on the 2009 FIGO staging showed 1 stage IA1 with lymphovascular invasion, 15 stage IA2, and 110 stage IB1 patients. Although not statistically significant, the 3-year disease-free survival (DFS) was higher in the open compared to the MIS group (95% vs 87%; p = .17), and the overall survival was higher in the open compared to the MIS group (97% vs 92%; p = .25). Fourteen patients whose disease recurred were Stage IB1 by FIGO 2009 staging; 11/14 were reclassified to a higher stage by 2018 FIGO staging (5/5 open, 6/9 MIS). Adjuvant therapy was recommended for all these patients based on the Sedlis criteria (10/14) or other risk factors (4/14). Despite this, only 1/9 of MIS patients whose disease recurred received adjuvant therapy compared with 3/5 patients whose disease recurred in the open group (p = .05). CONCLUSION: In a cohort of patients similar to that of the Laparoscopic Approach to Cervical Cancer trial, 2018 FIGO staging may be useful to refine indications for MIS radical hysterectomy in early stage cervical cancer. However, disparate outcomes between MIS and open approaches may be explained by differences in compliance with National Comprehensive Cancer Network guidelines for adjuvant therapy.

来源:J Minim Invasive Gynecol,查看原文。版权归原作者所有。

引用

  1. Levine MD, Brown J, Crane EK, et al. Outcomes of Minimally Invasive versus Open Radical Hysterectomy for Early Stage Cervical Cancer Incorporating 2018 FIGO Staging. J Minim Invasive Gynecol. 2020. PMID: 32730990. doi:10.1016/j.jmig.2020.07.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。